BillionToOne Overview
- Year Founded
-
2016
- Status
-
Private
- Employees
-
510
- Latest Deal Type
-
Debt Refin.
- Latest Deal Amount
-
$140M
- Investors
-
44
BillionToOne General Information
Description
Developer of a molecular diagnostics company intended to develop prenatal and oncology assays that are at the physical limit of sensitivity and precision. The company offers an ultrasensitive comprehensive genomic profiling assay that detects more actionable mutations for therapy selection and a pan-cancer tumor-naive oncology test that precisely quantifies tumor burden from a blood sample to track response to therapy and prenatal tests go beyond aneuploidies to detect single-gene disorders, enabling expecting mothers to detect disorders such as sickle-cell disease, beta-thalassemia, spinal muscular atrophy, and cystic fibrosis through a simple blood test.
Contact Information
Website
www.billiontoone.comCorporate Office
- 1035 O'Brien Drive
- Menlo Park, CA 94025
- United States
Corporate Office
- 1035 O'Brien Drive
- Menlo Park, CA 94025
- United States
BillionToOne Timeline
BillionToOne Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 11. Debt Refinancing | 04-Sep-2024 | $140M | Completed | Generating Revenue | ||
| 10. Later Stage VC (Series D) | 07-May-2024 | Completed | Generating Revenue | |||
| 9. Secondary Transaction - Private | Completed | Generating Revenue | ||||
| 8. Later Stage VC | 15-Dec-2022 | Completed | Generating Revenue | |||
| 7. Later Stage VC (Series C) | 16-Mar-2022 | Completed | Generating Revenue | |||
| 6. Later Stage VC (Series B) | 14-Jun-2021 | Completed | Generating Revenue | |||
| 5. Later Stage VC (Series A) | 22-Feb-2021 | Completed | Generating Revenue | |||
| 4. Grant | 01-Jan-2018 | Completed | Generating Revenue | |||
| 3. Seed Round | 30-Sep-2017 | $2.5M | $2.5M | Completed | Generating Revenue | |
| 2. Accelerator/Incubator | 22-Aug-2017 | Completed | Startup |
BillionToOne Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | ||||||||
| Series B-2 | ||||||||
| Series B-1 | ||||||||
| Series A-6 | ||||||||
| Series A-5 | ||||||||
| Series A-4 | ||||||||
| Series A-3 | ||||||||
| Series A-2 | 1,137,210 | $0.000010 | $0.8 | $0.8 | 1x | $0.8 | 3.05% | |
| Series A-1 | 1,349,650 | $0.000010 | $0.4 | $0.4 | 1x | $0.4 | 3.62% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
BillionToOne Comparisons
Industry
Financing
Details
BillionToOne Competitors (6)
One of BillionToOne’s 6 competitors is Foundation Medicine, a Formerly VC-backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Foundation Medicine | Formerly VC-backed | Cambridge, MA | ||||
| Natera | Formerly VC-backed | Austin, TX | ||||
| Myriad Genetics | Corporation | Salt Lake City, UT | ||||
| Guardant Health | Formerly VC-backed | Palo Alto, CA | ||||
| Tempus AI | Formerly VC-backed | Chicago, IL |
BillionToOne Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
News about BillionToOne
Dive into recent articles by PitchBook offering invaluable insights and context.
BillionToOne Patents
BillionToOne Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20230295741-A1 | Molecule counting of methylated cell-free dna for treatment monitoring | Active | 21-Mar-2022 | ||
| US-12043873-B2 | Molecule counting of methylated cell-free dna for treatment monitoring | Active | 21-Mar-2022 | ||
| AU-2023240345-A1 | Molecule counting of methylated cell-free dna for treatment monitoring | Pending | 21-Mar-2022 | ||
| EP-4496900-A2 | Molecule counting of methylated cell-free dna for treatment monitoring | Pending | 21-Mar-2022 | ||
| US-20240360519-A1 | Molecule counting of methylated cell-free dna for treatment monitoring | Pending | 21-Mar-2022 | C12Q1/6827 |
BillionToOne Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
BillionToOne Investors (44)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Neuberger Berman | Asset Manager | Minority | ||
| NYX Ventures Partners | Venture Capital | Minority | ||
| Premji Invest (US) | Growth/Expansion | Minority | ||
| Brightway Future Capital | Venture Capital | Minority | ||
| Eczacıbaşı Momentum | Corporate Venture Capital | Minority |
BillionToOne FAQs
-
When was BillionToOne founded?
BillionToOne was founded in 2016.
-
Where is BillionToOne headquartered?
BillionToOne is headquartered in Menlo Park, CA.
-
What is the size of BillionToOne?
BillionToOne has 510 total employees.
-
What industry is BillionToOne in?
BillionToOne’s primary industry is Diagnostic Equipment.
-
Is BillionToOne a private or public company?
BillionToOne is a Private company.
-
What is BillionToOne’s current revenue?
The current revenue for BillionToOne is .
-
How much funding has BillionToOne raised over time?
BillionToOne has raised $551M.
-
Who are BillionToOne’s investors?
Neuberger Berman, NYX Ventures Partners, Premji Invest (US), Brightway Future Capital, and Eczacıbaşı Momentum are 5 of 44 investors who have invested in BillionToOne.
-
Who are BillionToOne’s competitors?
Foundation Medicine, Natera, Myriad Genetics, Guardant Health, and Tempus AI are some of the 6 competitors of BillionToOne.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
